News

Supporters Poised for September, 10th World Alzheimer’s Month

Each September, people from around the globe come together to heighten awareness of Alzheimer’s disease and push back against stigmas around dementia. This year marks a decade of advocacy, as supporters observe the 10th World Alzheimer’s Month. Throughout the month, patients, caregivers, and advocates will share messages and stories…

All Patients in GAIN Trial Show Signs of Gum Disease Bacteria

Every participant in the Phase 2/3 GAIN clinical trial, which is testing Cortexyme’s experimental medication COR388 (atuzaginstat) in people with Alzheimer’s disease, showed evidence of infection by Porphyromonas gingivalis (P. gingivalis), according to a new analysis. In particular, all patients analyzed at the beginning of the study who had…

FDA OKs Phase 1 Trial of Nasal Spray Immunotherapy Protollin

I-Mab will launch a Phase 1 clinical trial evaluating Protollin, its nasal spray immunotherapy candidate for Alzheimer’s disease. The biotech company’s announcement follows the recent approval of an investigational new drug (IND) application for Protollin by the U.S. Food and Drug Administration (FDA). “Advancing Protollin into clinic is…

Man on Mission to Make Music Accessible for Dementia Patients

Note: An update to this story on Aug. 23, 2021, changed the percentage of assisted living facilities that have incorporated personalized music into their care from 3% to 10%, according to corrected information from Dan Cohen.  According to Dan Cohen, founder of the organization Right to Music, about 25,000…

Device to Spot Alzheimer’s Onset in Adults Recognized by FDA

Altoida’s artificial intelligence (AI)-powered device, intended to indicate the start of Alzheimer’s disease in adults with mild dementia but no evident disease symptoms, has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The non-invasive device uses a software that measures and monitors neurocognitive function to…